{
  "docId": "019de073-f2d4-7758-94ad-33c5441d40e0",
  "docSlug": "ecbf51e8e3db999397a90a848caaf022",
  "documentTitle": "BioAtla | Investor Presentation Deck | 40 slides",
  "authorId": "bioatla",
  "authorName": "BioAtla",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-11-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 31,
  "pageCount": 40,
  "prevPage": 30,
  "nextPage": 32,
  "slideType": "roadmap",
  "function": "plan_implementation",
  "density": "dense",
  "nDataPoints": 14,
  "notes": "The slide uses a timeline-based visualization to show dose escalation steps. RP2D = Recommended Phase 2 Dose. DLT = Dose Limiting Toxicity.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de073-f2d4-7758-94ad-33c5441d40e0/31",
  "deckHref": "/decks/019de073-f2d4-7758-94ad-33c5441d40e0",
  "deckJsonHref": "/decks/019de073-f2d4-7758-94ad-33c5441d40e0.json",
  "deckAnchorHref": "/decks/019de073-f2d4-7758-94ad-33c5441d40e0#slide-31",
  "components": [
    {
      "bbox": {
        "h": 0.5,
        "w": 0.5,
        "x": 0.05,
        "y": 0.22
      },
      "kind": "chart",
      "text": "Dose escalation timeline for BA3071 cohorts",
      "attrs": null,
      "subkind": "timeline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "8cfb3948-020f-49c8-bcc0-0f966800106d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.7,
        "x": 0.18,
        "y": 0.79
      },
      "kind": "list",
      "text": "Objectives: Determine Phase 2 dose and MTD; Characterize safety and clinical activity; Characterize PK, ADA and biomarkers",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "14c7ea35-198e-4dbe-980b-bf87d39ce73b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.4,
        "w": 0.2,
        "x": 0.7,
        "y": 0.36
      },
      "kind": "list",
      "text": "Possible Phase 2 Dose Expansion Cohorts: RCC, Melanoma, NSCLC, SCLC, Bladder, Gastric, aHCC, Cervical (all n=40)",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "5c9c2605-8f46-4a30-8501-47108e8c7ccc",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.4,
        "x": 0.03,
        "y": 0.14
      },
      "kind": "paragraph",
      "text": "in tumors known to be responsive to CTLA-4 treatment",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "0ae0e9fc-c38e-4467-9ef9-6a068b498479",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.3,
        "x": 0.11,
        "y": 0.94
      },
      "kind": "source-note",
      "text": "*Dose equivalent to approved ipilimumab dose (1 mg/kg)",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "55851263-5691-4dd7-a7bc-8f7040ba0bd6",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.6,
        "x": 0.03,
        "y": 0.08
      },
      "kind": "title",
      "text": "Phase 1/2 trial design for CAB-CTLA-4 Naked Antibody (BA3071)",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d85c2443-72f7-4749-8497-67ac3c03456f",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "gantt-chart",
      "slug": null,
      "matchId": "472d08e7-1180-40a5-aa8c-765a5a10505f",
      "evidence": "The timeline visualization of trial cohorts functions as a Gantt chart for clinical development.",
      "confidence": 0.8
    }
  ],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}